Iqvia Holdings is a global leader in advancing healthcare by providing data analytics, technology, and consulting services to the pharmaceutical and life sciences industries. The company specializes in helping organizations improve their clinical trials, optimize research and development processes, and enhance patient engagement. By leveraging its extensive data assets and innovative technology platforms, Iqvia aids clients in making informed decisions that drive efficiency and effectiveness in bringing new therapies to market. Read More
Shares of clinical research company IQVIA (NYSE: IQV)
fell 8.5% in the morning session after the company issued a weak full-year 2026 profit forecast that fell below Wall Street expectations.
Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025.
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering as the accelerator to power its global commercial data harmonization and transformation journey.
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2026 Fortune® World’s Most Admired Companies™ list.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
What a time it’s been for IQVIA. In the past six months alone, the company’s stock price has increased by a massive 51.4%, reaching $242.50 per share. This performance may have investors wondering how to approach the situation.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
In the complex ecosystem of modern medicine, few companies carry as much institutional weight—or stir as much controversy—as Charles River Laboratories International, Inc. (NYSE: CRL). As of December 23, 2025, Charles River stands as the indispensable backbone of the global pharmaceutical industry. It is a company that has, remarkably, participated in the development of over [...]
Artificial Intelligence (AI) stands at the precipice of revolutionizing healthcare, promising breakthroughs in diagnostics, personalized treatment, and operational efficiency. However, the path to widespread, ethical, and effective AI adoption in medical settings is fraught with significant challenges. As of December 12, 2025, the immediate significance of these hurdles—encompassing the critical need for trust, comprehensive clinician [...]
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as IQVIA’s Preferred Agentic Cloud Provider. The partnership, revealed at AWS re:Invent, is a major step in the digital transformation of healthcare and life sciences, aiming to revolutionize clinical trial automation, medical affairs and analytics through an innovative agentic AI platform.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
